

## Project ECHO for Interstitial Lung Disease

Wednesday, April 2, 2025, 7am-8am EST

Medical Director	Robert Hallowell, MD
Principal Investigator	Aliaa Barakat, PhD
Didactic Speaker	Lida Hariri, MD, PhD
Session Facilitator	Barry Shea, MD
Target Audience	The series is designed for pulmonologists, radiologists and other health providers who care for people with ILD.

**In accordance with HIPAA:** *All patient information will be de-identified during session.*

Time	Didactic Presentation / Case Discussion	Presenter / Facilitator
7:00am-7:05am	Announcements and Introductions	Aliaa Barakat, PhD
7:05am-7:25am	Didactic: Lung Biopsy in the Diagnosis of ILD	Lida Hariri, MD, PhD
7:25am-8:00am	Case Presentation and Discussion	Barry Shea, MD
8am	Closing Remarks	Aliaa Barakat, PhD



In support of improving patient care, this activity has been planned and implemented by the Pulmonary Care and Research Collaborative, Ltd. and Project ECHO®. Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



### AMA Designation Statement

Project ECHO® designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

### ECHO Activity ID: RSS943

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.

## Disclosure Statement

Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.

None of the following planners / presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Grace Peloquin, MD.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

Name	Nature of Relationship	Name of Ineligible Company
Aliaa Barakat, PhD	PI - Investigator-initiated research	Genentech, Inc.
Katharine Black, MD	Researcher	Bayer AG
Fiona Gibbons, MD	Researcher	aTyr Pharma
Leo Ginns, MD	Researcher	Genentech, Inc., Nitto Denko, United Therapeutics
Robert Hallowell, MD	Researcher	Boehringer Ingelheim
	Consultant	Vicore Pharma, UpToDate
	Advisor	The Myositis Association
Lida Hariri, MD, PhD	Researcher	Boehringer Ingelheim
	Consultant	Abbvie, Boehringer Ingelheim, Clario, Pliant Therapeutics,
Sydney Montesi, MD	PI - Investigator-initiated research	Boehringer Ingelheim
	Researcher	Pliant Therapeutics
	Consultant	Accendatech, DevPro Biopharma, Mediar Therapeutics, Roche
	Royalties or Patent Beneficiary	Wolters Kluwer
Peter LaCamera, MD	Researcher	Boehringer Ingelheim

All of the relevant financial relationships listed for these individuals have been mitigated.

### **ECHO Activity ID: RSS943**

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

Name	Nature of Relationship	Name of Ineligible Company
Barry Shea, MD	Researcher	Boehringer Ingelheim, Bristol Myers Squibb, FibroGen
	Consultant	Pipeline Therapeutics, Radius Health

All of the relevant financial relationships listed for these individuals have been mitigated.

**ECHO Activity ID: RSS943**

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.